rxprohealth - Custom e-Learning Portal


• home • catalog • help • login

An Evidence-Based Approach to Treating Seizures and Behavioral Disturbances in Individuals with Intellectual and Developmental Disabilities

Course Information

Back to Catalog

This lesson is supported by:

Provided by:

An Evidence-Based Approach to Treating Seizures & Behavioral Disturbances in Individuals with Intellectual and Developmental Disabilities

After completing this program, participants will be able to:

Describe the prevalence of seizure disorders in individuals with intellectual and developmental disabilities (I/DD) and consider issues in seizure control that are special to the I/DD population.
Discuss other psychiatric and neurological conditions which may cause behavioral disturbances in individuals with I/DD, including bipolar disorder, aggression, pervasive developmental disorders and self-injurious behavior.
Compare and contrast antiepileptic drugs based on safety and efficacy profiles, as well as drug-drug interactions in individuals with I/DD who often have complicated drug regimens.
Evaluate pharmacologic treatment of individuals with I/DD, considering simplification of administration, reduction of total medication burden, quality of life, ease of dosing and cost considerations.

Target Audience

Physicians, Pharmacists, and Nurses

Faculty

Program Chair
Michael C. Smith, MD
Director, Rush Epilepsy Center
Associate Professor of Neurology, Rush University Medical Center
Chicago, IL
Disclosure: Consultant: Abbott, Esai, GlaxoSmithKline, Ortho-McNeil, Ovation Pharmaceuticals, UCB Pharmaceuticals, and Valeant; Grant/Research Support: Neuropace; Honoraria: Abbott, Esai, GlaxoSmithKline, Ortho-McNeil, Ovation Pharmaceuticals, UCB Pharmaceuticals, and Valeant

Dean Naritoku, MD
Professor of Neurology and Pharmacology, Southern Illinois School of Medicine
Director, Center for Epilepsy
Springfield, IL
Disclosure: Consultant: Abbott, Ortho McNeil, and Eisai; Grant/Research Support: Pfizer; Honoraria: Abbott, Elan Pharmaceuticals, GlaxoSmithKline, Ortho-McNeil and UCB Pharma

Jessica Hellings, MD
Director, Neuro-Developmental Psychiatry for Children, Adolescents and Adults
Associate Professor, Psychiatry and Behavioral Sciences, Kansas University Medical Center
Kansas City, KS
Disclosure: Consultant: Abbott; Grant/Research Support: Abbott

Technologies Used

Macromedia Flash

Price: FREE!

ACPE Accreditation
	ABcomm, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This home study web activity has been assigned a maximum of 3 credit hours (0.3 CEU) and the ACPE UPN: 811-000-06-002-H01. This accreditation expires on 12/08/2009.
	To receive educational credit, participants must complete an online evaluation form and pass the online assessment with a score of 70% or better. If you do not receive a minimum score of 70% or better, you are permitted 1 retake(s). After passing the assessment, you can view, print and track your statements of credit online. There is no fee to participate in this activity.

ACCME Accreditation
	ABcomm, Inc. is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. This home study web activity has been assigned a maximum of 3 AMA PRA Category 1 Credits™. This accreditation expires on 12/08/2009.
	To receive educational credit, participants must complete an online evaluation form and pass the online assessment with a score of 70% or better. If you do not receive a minimum score of 70% or better, you are permitted 1 retake(s). After passing the assessment, you can view, print and track your statements of credit online. There is no fee to participate in this activity.

AANP Accreditation
	ABcomm, Inc. is an approved provider of nurse practitioner continuing education by the American Academy of Nurse Practitioners. Approved Provider Number 040811. This home study web activity has been assigned a maximum of 3 credit hours. This accreditation expires on 12/08/2009.
	To receive educational credit, participants must complete an online evaluation form and pass the online assessment with a score of 70% or better. If you do not receive a minimum score of 70% or better, you are permitted 1 retake(s). After passing the assessment, you can view, print and track your statements of credit online. There is no fee to participate in this activity.

The material presented here does not reflect the views of Pharmacy Choice, Inc., RxSchool, or the companies providing educational content. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.
This lesson is supported by:

Home | Help | Catalog | Login